Q3 EPS Estimate for Acrivon Therapeutics Raised by Analyst

Key Points

• HC Wainwright raised Acrivon Therapeutics’ Q3 2026 EPS estimate to a loss of $0.48 per share from a previous loss estimate of $0.53. The company’s latest quarterly results also beat expectations, reporting a $0.43-per-share loss versus the $0.50 consensus estimate.
• Acrivon has a “Moderate Buy” consensus rating from analysts, with three Buy ratings and one Sell rating and an average price target of $13.50. Weiss Ratings separately downgraded the stock to “sell (e+).”
• ACRV opened at $1.95, with an $83.46 million market capitalization and a 12-month trading range of $1.27 to $3.56. Institutional investors own approximately 71.62% of the company.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Stock analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for Acrivon Therapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.48) per share for the quarter, up from their previous forecast of ($0.53). The consensus estimate for Acrivon Therapeutics' current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Acrivon Therapeutics' Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($1.31) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.60) EPS.

Separately, Weiss Ratings downgraded Acrivon Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $13.50.

Acrivon Therapeutics Stock Performance

ACRV opened at $1.95 on Monday. Acrivon Therapeutics has a 12-month low of $1.27 and a 12-month high of $3.56. The business's fifty day simple moving average is $1.68 and its 200-day simple moving average is $1.68. The company has a market capitalization of $83.46 million, a price-to-earnings ratio of -1.04 and a beta of 1.85.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.07.

Institutional Trading of Acrivon Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in Acrivon Therapeutics by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 198,223 shares of the company's stock valued at $478,000 after buying an additional 6,190 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Acrivon Therapeutics by 1.7% in the fourth quarter. Renaissance Technologies LLC now owns 634,169 shares of the company's stock worth $1,528,000 after acquiring an additional 10,769 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Acrivon Therapeutics in the fourth quarter worth about $40,000. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Acrivon Therapeutics during the fourth quarter worth about $44,000. Finally, Focus Partners Wealth purchased a new stake in shares of Acrivon Therapeutics during the third quarter worth about $36,000. Institutional investors and hedge funds own 71.62% of the company's stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics NASDAQ: ACRV is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source